SCHEMBL2767441

SCHEMBL2767441

O=C(c1ccccc1)N1CCN(c2ccc(O)cc2)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.74
ALDH1A1 P00352 3/20 0.74
POLB P06746 2/20 0.71
USP2 O75604 3/20 0.69
MAPT P10636 2/20 0.69
HSD17B10 Q99714 2/20 0.69
GAA P10253 1/20 0.69
ALOX15 P16050 1/20 0.69
HTT P42858 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
MAPK1 P28482 2/20 0.69
TSHR P16473 2/20 0.69
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
SLC6A7 Q99884 2/20 0.67
DRD2 P14416 1/20 0.64
HTR2A P28223 1/20 0.64
ME2 P23368 2/20 0.61
ME1 P48163 2/20 0.61
ME3 Q16798 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22627287 0.91 LMNA (0.70) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL8595777 0.90 POLB (0.87) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL2454898 0.87 NPC1 (0.69) ALDH1A1POLBUSP2MAPTHSD17B10
SCHEMBL10721777 0.86 MEN1 (0.87) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL23008892 0.85 SMN1; SMN2 (0.75) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL24641653 0.85 LMNA (0.72) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL23244314 0.85 MAPK1 (0.67) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL23244290 0.84 ME2 (0.62) LMNAALDH1A1POLBUSP2MAPT
SCHEMBL3577850 0.84 HSP90AA1 (0.76) LMNAALDH1A1USP2MAPTHSD17B10
SCHEMBL1481892 0.84 POLB (0.72) LMNAALDH1A1POLBUSP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
CN-100467449-C Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2009-03-11 CN disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
CN-1823039-A Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2006-08-23 CN disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed
EP-1567511-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
WO-2004035556-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS HRH3, HRH4, HRH2 LMNA 4344/4885ALDH1A1 1903/4885POLB 3375/4885
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA LMNA 3963/4885ALDH1A1 2953/4885POLB 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.